HIV integrase inhibitors - Pipeline Insight, 2024

This “HIV integrase inhibitors - Pipeline Insight, 2024,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in HIV integrase inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

HIV integrase inhibitors Understanding

HIV integrase inhibitors: Overview

Retroviral integrase (IN) is an enzyme produced by a retrovirus (such as HIV) that integrates - forms covalent links between - its genetic information into that of the host cell it infects. Integrase inhibitors affect the way HIV works in the body.

Function -HIV integrase is a 32 kDa protein produced from the C-terminal portion of the Pol gene product, and is an attractive target for new anti-HIV drugs. The main function of IN is to insert the viral DNA into the host chromosomal DNA, a step that is essential for HIV replication. Integration is a point of no return for the cell, which becomes a permanent carrier of the viral genome (provirus). Integration is in part responsible for the persistence of retroviral infections.[citation needed] After integration, the viral gene expression and particle production may take place immediately or at some point in the future, the timing of which depends on the activity of the chromosomal locus hosting the provirus.

HIV integrase inhibitors- Integrase inhibitors rely on the fact that HIV needs integrase to replicate. These drugs stop HIV from being able to make integrase. Without the help of this enzyme, HIV can’t take over the T cells to copy itself.

HIV integrase inhibitors Emerging Drugs Chapters

This segment of the HIV integrase inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

HIV integrase inhibitors Emerging Drugs

Cabotegravir: ViiV Healthcare Cabotegravir (CAB), an analog of dolutegravir, prevents viral DNA integration into the host genome and inhibits HIV replication. CAB is being developed for both HIV treatment and HIV prevention. It is currently in phase 3 of clinicaldevelopment.

Bictegravir : Gilead Sciences The bictegravir contained in Biktarvy® is an integrase strand transfer inhibitor that prevents the replication of the HIV 1 virus by blocking HIV-1 integrase, an enzyme required for replication of HIV virus. It also blocks the formation and propagation of HIV-1 provirus. It is currently in phase 1 of clinical trials.

HIV integrase inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different HIV integrase inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on HIV integrase inhibitors

There are approx. 3+ key companies which are developing the HIV integrase inhibitors. The companies which have their HIV integrase inhibitors drug candidates in the most advanced stage, i.e. phase III include, ViiV Healthcare.

Phases

This report covers around 3+ products under different phases of clinical development like

• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

HIV integrase inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical.

Molecule Type

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

HIV integrase inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses HIV integrase inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging HIV integrase inhibitors drugs.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence HIV integrase inhibitors R&D. The therapies under development are focused on novel approaches for HIV integrase inhibitors.

HIV integrase inhibitors Report Insights

• HIV integrase inhibitors Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

HIV integrase inhibitors Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

• How many companies are developing HIV integrase inhibitors drugs?
• How many HIV integrase inhibitors drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for HIV integrase inhibitors?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the HIV integrase inhibitors therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for HIV integrase inhibitors and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• ViiV Healthcare
• Gilead Sciences
• GlaxoSmithKline

Key Products

• Cabotegravir injection
• Bictegravir
• GSK 3640254